
    
      Approximately 170 subjects will be randomized 1:1 in approximately 40 sites in China. This
      study consists of a screening period of up to 28 days, followed by a treatment period of 18
      weeks, and an end of study visit 3 weeks after the last dose of investigational product or
      study-specified chemotherapy. After randomization, subjects will receive investigational
      product at a dose of 15 mg/kg administered every 3 weeks for 6 cycles followed by at least 4
      and no more than 6 cycles of carboplatin and paclitaxel chemotherapy every 3 weeks.
    
  